Clinical Trials Directory

Trials / Completed

CompletedNCT00055146

Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

A Multicenter, Phase II Study of ONTAK (Denileukin Diftitox) in Patients With Previously-Treated Chronic Lymphocytic Leukemia

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
41 (estimated)
Sponsor
Eisai Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with chronic lymphocytic leukemia (CLL)

Conditions

Interventions

TypeNameDescription
DRUGONTAK

Timeline

Start date
2003-03-01
Primary completion
2006-03-01
Completion
2006-05-01
First posted
2003-02-21
Last updated
2009-04-17

Locations

14 sites across 5 countries: United States, Argentina, Australia, Brazil, Canada

Source: ClinicalTrials.gov record NCT00055146. Inclusion in this directory is not an endorsement.

Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) (NCT00055146) · Clinical Trials Directory